(E)-环辛-4-烯醇/赤道-TCO/E | 4277-34-3

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 环烃
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (E)-环辛-4-烯醇/赤道-TCO/E
• 英文名称: Cyclooct-4-en-1-ol
• 英文别名: 5-Hydroxy-1-cyclooctene；(1S,4Z)-cyclooct-4-en-1-ol
• CAS: 4277-34-3；31598-74-0；39637-78-0；39637-79-1；39638-01-2；85081-69-2
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: UCPDHOTYYDHPEN-SLYZXXNYSA-N

物化性质

• 沸点：
  87.5-90 °C(Press: 10 Torr)
• 密度：
  0.95g/ml

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  (E)-环辛-4-烯醇/赤道-TCO/E 在 10% silver nitrate adsorbed on silica 作用下， 以73%的产率得到(E)-cyclooct-4-enol
  参考文献：
  名称：

  Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels−Alder Reactivity

  摘要：

  Described is a bioorthogonal reaction that proceeds with unusually fast reaction rates without need for catalysis: the cycloaddition of s-tetrazine and trans-cyclooctene derivatives. The reactions tolerate a broad range of functionality and proceed in high yield in organic solvents, water, cell media, or cell lysate. The rate of the ligation between trans-cyclooctene and 3,6-di-(2-pyridyl)-s-tetrazine is very rapid (k(2) 2000 M-1 s(-1)). This fast reactivity enables protein modification at low concentration.

  DOI：

  10.1021/ja8053805
• 作为产物：
  描述：

  (Z)-cyclooct-4-en-1-yl (1R,4S)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以52 %的产率得到(E)-环辛-4-烯醇/赤道-TCO/E
  参考文献：
  名称：

  [EN] METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF A SYMMETRICAL DIENE
  [FR] PROCÉDÉ PERMETTANT D'OBTENIR UN VECTEUR CIBLANT UNE ENTITÉ CHIMIQUE MONOISOMÈRE MARQUÉ À BASE DE L'UTILISATION D'UN DIÈNE SYMÉTRIQUE

  摘要：

  The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.

  公开号：

  WO2023170164A1

文献信息

• Heterotricyclodecane VIII. (?)-(1S,3R,6R,8R)-2, 7-Dioxaisotwistan und (?)-(1R,3R,6R,8R)-2, 7-Dioxa-twistan; Synthese und Bestimmung der absoluten Konfiguration
  作者：P. Ackermann、H. Tobler、C. Ganter

  DOI：10.1002/hlca.19720550806

  日期：1972.11.1

  A synthesis and the determination of the absolute configuration of (−)-(1S, 3R′ 6R, 8R)-2, 7-dioxa-isotwistane (13) and (−)-(1R, 3R, 6R, 8R)-2, 7-dioxa-twistane (14) is described. The results for 14 are compared with those for carboeyclic (+)-twistane (2) of known chirality.

  （-）-（1S， 3R'6R ，8R）-2，7-二氧杂异丁烷（13）和（-）-（1R，3R，6R，8R）-2的合成和绝对构型的确定，描述了7-二氧杂-叔丁基（14）。将14个的结果与已知手性的碳环（+）-twistane（2）的结果进行比较。
• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：Koninklijke Philips N.V.

  公开号：EP2709666A1

  公开（公告）日：2014-03-26
• [EN] BIO-ORTHOGONAL DRUG ACTIVATION<br/>[FR] ACTIVATION D'UN MÉDICAMENT BIO-ORTHOGONAL
  申请人：KONINKL PHILIPS ELECTRONICS NV

  公开号：WO2012156918A1

  公开（公告）日：2012-11-22

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.